Points to consider when defining a microbial control strategy...

Presented by

Friedrich von Wintzingerode, PhD, QC Lead iNeST Project (individualized Neoantigen Specific Therapy)

About this talk

Full title: Points to consider when defining a microbial control strategy for individualized ATMPs How are individualized ATMPs different from traditional drugs and off-the-shelf ATMPs? Regulatory background Microbiological testing: be smart and keep it simple The importance of raw material control ATMPs: A mindset challenge for Microbiologists
Related topics:

More from this channel

Upcoming talks (25)
On-demand talks (369)
Subscribers (36872)
BioPharma Webinars aims to keep its global audience abreast of all developments in the areas of Drug Development, Manufacturing, Quality Assurance, Outsourcing and Regulatory Affairs, with only the highest quality webinars, presented by the most respected people, working with companies in Pharmaceutical, Biopharmaceutical, Biologics and Biotech Industry.